1. Home
  2. Medical News
  3. Dermatology
advertisement

Argon Plasma Improves Atopic Dermatitis Scores in Small Trial

Illustrated skin cross section showing localized eczematous inflammation associated with atopic dermatitis
11/18/2026

Key Takeaways

  • Adults with mild-to-moderate atopic dermatitis at a South Korean hospital had significantly improved eczema severity, itch, and quality-of-life scores after non-thermal argon plasma treatment versus sham at week four.
  • No serious adverse events were observed during the trial, although longer-term safety remains unknown.
  • Skin bacterial composition shifted after plasma exposure, and within-sample diversity declined significantly only in non-lesional skin.
  • Inflammatory and oxidative markers fell in plasma-treated mice, while cultured keratinocytes showed NRF2-associated antioxidant activity; neither finding establishes a human mechanism.
Itch, acute eczematous lesions, and impaired quality of life burden adults with mild-to-moderate atopic dermatitis. Localized non-thermal argon plasma (NAP) raises the question of whether treatment directed at affected skin can ease these symptoms. Whether changes in skin bacteria or inflammatory pathways accompany any clinical response remains uncertain.

In Park and colleagues’ randomized sham-controlled argon plasma study, investigators assigned 15 adults at Ajou University Hospital, South Korea, to active NAP (10) or an appearance-, sound-, and sensation-matched sham (5) in a double-blind, parallel-group phase I comparison.

Five lesions received one minute of irradiation per visit, with nine applications in total. Treatment spanned four weeks. Efficacy was assessed from baseline to visit V10 at week four; a further two-week period without treatment monitored safety.

Prespecified primary change measures were the Eczema Area Severity Index (EASI) and investigator global assessment (IGA); secondary measures included the pruritus Numeric Rating Scale (NRS), Dermatology Life Quality Index (DLQI), and transepidermal water loss. Observers were blinded, and photographs underwent independent assessment. Investigators also profiled lesional and non-lesional skin using 16S ribosomal ribonucleic acid (rRNA) sequencing and conducted separate house dust mite–induced mouse dermatitis and HaCaT keratinocyte experiments.

At week four, EASI, pruritus NRS, and DLQI scores declined significantly more with active NAP than with sham. No serious adverse events were observed during the trial. Transepidermal water loss and total immunoglobulin E (IgE) did not change significantly.

After NAP exposure, skin profiling showed increased Lactobacillus and Burkholderia-Caballeronia-Paraburkholderia and decreased Staphylococcus; within-sample alpha-diversity fell significantly only in non-lesional skin. In mice with house dust mite–induced dermatitis, plasma treatment reduced epidermal thickening, mast-cell and eosinophil recruitment, interleukin-33 (IL-33)–associated signaling, and reactive oxygen and nitrogen species. An inhibitor of nuclear factor erythroid 2–related factor 2 (NRF2) diminished the antioxidant activity of plasma-treated liquid in cultured keratinocytes. These laboratory observations were separate from the human symptom assessments.

Park and colleagues identified the small exploratory sample, brief post-treatment monitoring, and retrospective registration after participant follow-up as constraints. They acknowledged possible selective-reporting bias while stating that clinical outcomes had been prespecified in the institutional review board–approved protocol. Participants predominantly had acute lesions, leaving effects in chronic or severe atopic dermatitis unestablished. The skin microbiome associations do not demonstrate causal mediation of clinical improvement, and the proposed oxidative stress and IL-33 pathway was not demonstrated directly in human skin.

Park and colleagues regard the observed symptom changes as a potential short-term signal, not an established treatment effect across broader populations. The authors call for larger, prospectively registered trials with longer efficacy and safety follow-up to assess that signal.

Clinician Questions

Were topical treatments allowed during non-thermal argon plasma treatment for atopic dermatitis?

In the trial involving adults with mild-to-moderate atopic dermatitis, topical emollients were allowed, other concomitant therapies were prohibited, and investigator-directed topical mometasone furoate was available as rescue medication.

Did non-thermal argon plasma affect Staphylococcus aureus and Lactobacillus plantarum equally in laboratory testing?

No. In Park and colleagues’ separate in-vitro bacterial assay related to atopic dermatitis, liquid treated with non-thermal argon plasma eradicated Staphylococcus aureus, whereas Lactobacillus plantarum was more resistant. That laboratory contrast does not establish that altered skin bacteria caused clinical improvement in human atopic dermatitis.

Recommended Reading

This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.

This content is intended for healthcare professionals for educational purposes. The article and its image were developed with AI assistance and reviewed by members of the ReachMD team prior to publication. Please refer to the original source linked for the complete and most up-to-date information.

Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free